Bio Business

» biotech, tuberculosis and pharma

Most Recent

image: Oligonucleotide Therapeutics Near Approval

Oligonucleotide Therapeutics Near Approval

By | December 1, 2016

Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.

0 Comments

image: The Growth of Iowa Biotech

The Growth of Iowa Biotech

By | August 1, 2016

The state’s industry draws inspiration from medicine as well as agriculture.

1 Comment

image: The Sounds of Silence

The Sounds of Silence

By | September 1, 2015

Science-based tinnitus therapeutics are finally coming into their own.

3 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: Incubator Boom

Incubator Boom

By | March 1, 2014

From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?  

2 Comments

image: Outwitting the Perfect Pathogen

Outwitting the Perfect Pathogen

By | January 1, 2014

Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.

0 Comments

image: Penetrating the Brain

Penetrating the Brain

By | November 1, 2013

Researchers use molecular keys, chisels, and crowbars to open the last great biochemical barricade in the body—the blood-brain barrier.

3 Comments

image: Remaking a Classic

Remaking a Classic

By | September 1, 2013

Companies are bursting at the seams with tools to engineer pharma’s next magic bullet: the new and improved antibody.

0 Comments

image: The Little Cell That Could

The Little Cell That Could

By | July 1, 2012

Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.

1 Comment

image: Braving the IPO Drought

Braving the IPO Drought

By | March 1, 2012

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.

0 Comments

Popular Now

  1. Unstructured Proteins Help Tardigrades Survive Desiccation
  2. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  3. Opinion: On “The Impact Factor Fallacy”
  4. Inflammation Drives Gut Bacteria Evolution
Business Birmingham